Phase I – Bioequivalence

295 trials 18 recruiting

Filter these 295 trials by condition, country, sponsor and more.

Open in Search →

KF2025#1 trial: Ketamine, cannabidiol and cobicistat interaction study Ended

2025-523817-27-00 Terveet vapaaehtoiset tutkittavat 2026-03-05
An open-label, randomized, single-dose, three-way crossover trial to evaluate the pharmacokinetics of nicotine pouch (NP) dry 4 mg compared … Ended

2025-523879-34-00 Nicotine use 2025-11-17
An open label, balanced, randomized, two-treatment, four-period, two-sequence, single-dose, crossover fully replicate bioequivalence study c… Ended

2025-520617-31-00 ulcerative colitis 2025-09-12
Assessment of Pharmacokinetic Similarity of FYB206 in Comparison with Keytruda in Resected Stage II or Stage III Melanoma Patients Ended

2023-509765-20-00 Melanoma: Adjuvant treatment of patients with Stage IIB 2024-10-21
Study which tests 3 medicines (SB27, EU sourced Keytruda, and US sourced Keytruda) in early or locally advanced non-small cell lung cancer p… Ended

2023-507438-25-00 Non-small cell lung cancer 2024-02-28
To assess the relative BA of a low-strength FDC tablet formulation of niraparib plus AA compared to niraparib and AA co-administered as sing… Ended

2023-508150-26-00 Metastatic castration-resistant prostate cancer (mCRPC) 2020-11-26
Study of Abemaciclib with Pembrolizumab in Patients with Stage IV Lung Cancer or Breast Cancer Ended

2023-506788-32-00 Lung Cancer or Breast Cancer 2016-11-15
A Phase 1b, Multicenter, Open-label Study of Acalabrutinib in Combination with Bendamustine and Rituximab (BR) or Venetoclax and Rituximab (… Ended

2023-509353-31-00 Mantle Cell Lymphoma 2016-09-05
Bioequivalence study 2 to compare pharmacokinetics of Parkinson´s disease drugs in healthy volunteers Ended

2026-525449-57-00 Parkinson desease 2026-04-08
Bioequivalence Study of Empagliflozin Ended

2026-525434-33-00 Not applicable (submitted trial is a BE study in health 2026-04-07
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study comparing Deucrava… Ended

2025-523838-13-00 plaque psoriasis 2026-03-24
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study comparing Deucrava… Ended

2025-523839-18-00 plaque psoriasis 2026-03-24
The pilot bioavailability study comparing the absorption of carbetocin (which is used as prevention of heavy bleeding after childbirth) in P… Ended

2025-524768-39-00 Not applicable (submitted trial is a bioavalability stu 2026-03-13
Single dose, open-label, laboratory blinded, randomized, 2-treatment, 2-period, 2-sequence, crossover, pivotal study to assess the relative … Ended

2025-521732-11-00 No medical condition 2026-03-09
A bioequivalence study comparing Empagliflozin 25 mg film-coated tablets, VIANEX S.A., Greece versus Jardiance 25 mg film-coated tablets, Bo… Ended

2025-524910-28-00 none - healthy volunteers 2026-03-09
Bioavailability study with naloxone hydrochloride in healthy volunteers Ended

2024-517838-17-00 No therapeutic indication in the current trial with hea 2026-03-06
Bioequivalence clinical trial of two formulations of rosuvastatin. Ended

2026-525230-27-00 Hypercholesterolemia 2026-02-23
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Lisdexa… Ended

2025-521224-29-00 ADHD (Attention Deficit Hyperactivity Disorder) 2026-02-20
Study to compare drug availability in the bloodstream of two oral formulations of dexketoprofen in healthy volunteers under fasting conditio… Ended

2025-524061-24-01 Bioequivalence clinical trial in healthy volunteers und 2026-02-13
A randomized, three-period, single-dose crossover trial in healthy female volunteers to demonstrate bioequivalence of tafoxiparin following … Ended

2025-521140-38-00 Labor priming 2026-02-11
A Randomised, Open-Label, Single-Centre, Study to Evaluate the Bioequivalence of Lanifibranor Ended

2025-524385-18-00 Non-alcoholic steatohepatitis 2026-02-11
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Clarith… Ended

2024-520153-21-00 Infectious diseases 2026-01-29
Bioequivalence of Testosterone Transdermal Gel in Healthy Female Participants. Ended

2025-523300-77-00 No medical conditions. 2026-01-26
An open label, randomized, single-dose, two-treatment, two-period, cross-over bioequivalence study comparing Pyridostigmine Bromide, P.R.Tab… Ended

2025-524218-27-00 treatment of myasthenia gravis 2026-01-21